DDrare: Database of Drug Development for Rare Diseases

Wd-1603 carbidopa and levodopa extended-release tablets (DrugBank: Carbidopa, Levodopa)

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04513340 (ClinicalTrials.gov)	August 13, 2020	12/8/2020	WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects	AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS	Parkinson Disease	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04513340
(ClinicalTrials.gov)

August 13, 2020

12/8/2020

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS

Parkinson Disease

Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

Hong Kong WD Pharmaceutical Co., Limited

NULL

Recruiting

18 Years

45 Years

All

Phase 1

India